MARKET

CABA

CABA

Cabaletta Bio, Inc.
NASDAQ
2.680
-0.140
-4.96%
After Hours: 2.680 0 0.00% 19:35 03/27 EDT
OPEN
2.790
PREV CLOSE
2.820
HIGH
2.950
LOW
2.630
VOLUME
2.80M
TURNOVER
--
52 WEEK HIGH
3.780
52 WEEK LOW
0.9857
MARKET CAP
298.34M
P/E (TTM)
-1.2758
1D
5D
1M
3M
1Y
5Y
1D
Pfizer To Rally More Than 34%? Here Are 10 Top Analyst Forecasts For Tuesday
Benzinga · 3d ago
Cabaletta Bio Price Target Cut to $13.00/Share From $14.00 by Morgan Stanley
Dow Jones · 3d ago
Cabaletta Bio Is Maintained at Overweight by Morgan Stanley
Dow Jones · 3d ago
Cabaletta Bio Is Maintained at Buy by Guggenheim
Dow Jones · 3d ago
Cabaletta Bio Price Target Raised to $16.00/Share From $15.00 by Guggenheim
Dow Jones · 3d ago
Morgan Stanley Maintains Overweight on Cabaletta Bio, Lowers Price Target to $13
Benzinga · 3d ago
Guggenheim Maintains Buy on Cabaletta Bio, Raises Price Target to $16
Benzinga · 3d ago
Wells Fargo Issues a Hold Rating on Cabaletta Bio (CABA)
TipRanks · 3d ago
More
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.

Webull offers Cabaletta Bio Inc stock information, including NASDAQ: CABA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CABA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CABA stock methods without spending real money on the virtual paper trading platform.